In this study, the TLR9 agonist CpG promoted the overexpression of iNOS and IL-12, while the combined treatment with anti-PD-L1 antibodies reeducated macrophages in GBM and enhanced the response to radiotherapy. Here, CD274 is linked to glioblastoma.